Welcome to our dedicated page for Aurinia Pharmace news (Ticker: AUPH), a resource for investors and traders seeking the latest updates and insights on Aurinia Pharmace stock.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) news covers the company’s progress as a biopharmaceutical issuer focused on therapies for autoimmune diseases with high unmet medical needs. Investors and followers of AUPH can use this page to review company‑issued updates, financial announcements and clinical data disclosures that shape the outlook for its products and pipeline.
News releases from Aurinia frequently highlight commercial performance and medical data for LUPKYNIS (voclosporin), which the company describes as the first FDA‑approved oral therapy for adult patients with active lupus nephritis. Regular quarterly earnings announcements detail trends in net product sales of LUPKYNIS, license, collaboration and royalty revenue, net income and cash flows. These updates are often accompanied by guidance ranges for total revenue and net product sales, as well as information on the company’s share repurchase plan.
In addition to financial results, Aurinia’s news flow includes clinical and scientific milestones. The company has reported post‑hoc analyses from the AURORA 1 trial, real‑world data from the ENLIGHT‑LN registry and new mechanistic findings on voclosporin, often presented at major rheumatology and nephrology meetings. Separate announcements describe progress with aritinercept (AUR200), a dual BAFF and APRIL inhibitor, including Phase 1 study results and plans for further clinical development in autoimmune diseases.
Visitors to this AUPH news page can review a stream of earnings releases, pipeline updates, medical conference presentations and regulatory‑related communications drawn from company press releases and SEC‑referenced materials. This provides a centralized view of how Aurinia communicates its commercial performance, clinical findings and strategic steps in autoimmune disease drug development.
Aurinia Pharmaceuticals (NASDAQ:AUPH) agreed to acquire Kezar Life Sciences (NASDAQ:KZR) for $6.955 cash per share plus one non-transferable contingent value right (CVR) tied to zetomipzomib development, certain collaboration/sale proceeds, and >100% of Kezar closing net cash above $50 million.
The tender offer will commence by April 13, 2026; closing is conditioned on majority tender, Kezar closing net cash exceeding $50 million net of CVR-related expenses, and customary conditions, with completion expected in Q2 2026.
MKT Capital, a long-term shareholder, praised Aurinia Pharmaceuticals (NASDAQ: AUPH) leadership changes after the Board removed CEO Peter Greenleaf and appointed Kevin Tang as CEO effective March 23, 2026. Key actions include CEO zero compensation, a $150 million share repurchase, discontinuing non-core R&D saving >$50 million annually, Board reduction from nine to six, and replacing time-based RSUs with performance awards.
MKT Capital says these moves conclude multi-year activist efforts and aim to prioritize disciplined capital allocation, shareholder alignment, and commercial execution for LUPKYNIS and AUR200.
Aurinia (NASDAQ: AUPH) announced a leadership transition on March 23, 2026: Kevin Tang, chair of the board, will succeed Peter Greenleaf as CEO, and Greenleaf will remain as a consultant to support the handover. The company named Ryan Cole as COO, Michael Hearne as CFO and Thomas Wei as CSO.
The announcement highlights LUPKYNIS as emerging therapy for lupus nephritis and notes that lead pipeline candidate aritinercept is advancing through clinical studies. Stew Kroll and Stephen Robertson remain as chief development officer and general counsel.
Aurinia Pharmaceuticals (NASDAQ: AUPH) reported 2025 results: total revenue $283.1M (+20%) and LUPKYNIS net product sales $271.3M (+25%). Net income was $287.2M driven by a $173.0M income tax benefit from releasing a valuation allowance. Cash and investments were $398.0M; the company repurchased 12.2M shares for $98.2M. For 2026 Aurinia guides total revenue $315M–$325M and LUPKYNIS sales $305M–$315M. The company plans additional clinical starts for aritinercept in H1 2026.
Aurinia Pharmaceuticals (NASDAQ: AUPH) will report financial results for the three and twelve months ended December 31, 2025, and provide a business update on February 26, 2026.
Management will host a webcast and conference call on February 26, 2026 at 8:30 a.m. ET; call dial-ins and a replay will be available on the company website.
Aurinia Pharmaceuticals (NASDAQ: AUPH) reported results for the three and nine months ended September 30, 2025, showing continued commercial momentum for LUPKYNIS and progress on clinical programs.
Key figures: Q3 total revenue $73.5M (+8% YoY); 9M revenue $205.9M (+17% YoY). Q3 LUPKYNIS net product sales $70.6M (+27% YoY); 9M LUPKYNIS sales $197.2M (+24% YoY). Net income was $31.6M Q3 and $76.4M 9M; diluted EPS $0.23 Q3 and $0.55 9M. Operating cash flow was $44.5M Q3 and $90.0M 9M.
The company raised 2025 guidance to $275–$280M total revenue and $265–$270M net product sales, repurchased 12.2M shares for $98.2M, and reported cash, equivalents and investments of $351.8M. Aurinia also noted positive Phase 1 aritinercept results and plans to start clinical studies in two autoimmune diseases by year-end.
Aurinia Pharmaceuticals (NASDAQ: AUPH) will report financial results for the three and nine months ended September 30, 2025 and provide a business update on November 4, 2025.
Management will host a webcast and conference call on November 4, 2025 at 8:30 a.m. ET. The webcast link is available on the company website and a replay will be posted following the event. Dial-in numbers for the call are 877-407-9170 (US) and +1 201-493-6756 (international).
Aurinia (NASDAQ: AUPH) announced five new posters presenting data on LUPKYNIS (voclosporin) at two upcoming meetings: ACR Convergence 2025 in Chicago, IL (October 24–29, 2025) and ASN Kidney Week 2025 in Houston, TX (November 5–9, 2025).
ACR posters cover real‑world effectiveness from the ENLIGHT‑LN registry and pediatric post‑marketing data. ASN posters include mechanistic tissue distribution studies, drug interactions with ketoconazole and rifampin, and ENLIGHT‑LN analyses on concomitant biologic use. Presenters include independent investigators and Aurinia medical lead Ernie Yap, M.D.
The company frames the data as contributing to real‑world and mechanistic understanding of voclosporin in lupus nephritis.
Aurinia Pharmaceuticals (NASDAQ: AUPH) has issued a response to address a retracted LinkedIn post by an FDA official regarding voclosporin. The company firmly stands behind the safety and efficacy profile of LUPKYNIS®, their FDA-approved lupus nephritis treatment.
The company emphasized that LUPKYNIS received full FDA approval in January 2021 based on the AURORA 1 study, and later secured additional approval in April 2024 for long-term use based on the AURORA 2 study, which demonstrated sustained efficacy over three years with comparable safety to AURORA 1.
Aurinia Pharmaceuticals (NASDAQ: AUPH) reported strong Q2 2025 financial results, with total revenue reaching $70.0 million, up 22% year-over-year. LUPKYNIS net product sales increased 21% to $66.6 million in Q2 2025.
The company achieved significant profitability with Q2 net income of $21.5 million and generated $45.5 million in operating cash flow for H1 2025. Aurinia raised its 2025 guidance, now expecting total revenue of $260-270 million and net product sales of $250-260 million.
The Board approved an additional $150 million for share repurchases, following previous buybacks of 18.3 million shares for $138.4 million. The company also reported positive Phase 1 results for aritinercept, planning to initiate clinical studies in multiple autoimmune diseases.